🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  2. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 3 small molecule active

    1 trial

  3. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  4. Atropine sulfate eye drops 0.01%

    China SXT Pharmaceuticals

    Myopia

    phase 3 small molecule active

    1 trial

  5. Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule

    Medice Arzneimittel Pütter GmbH & Co. KG

    Patients with ADHD (according to ICD-10 / DSM-5)

    phase 3 small molecule active

    1 trial

  6. Atumelnant

    Crinetics Pharmaceuticals Europe GmbH

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    2 trials

  7. Avexitide

    Amylyx Pharmaceuticals EMEA B.V.

    Post Bariatric Hypoglycemia

    phase 3 small molecule active

    1 trial

  8. Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE

    Pharma Mar S.A.

    Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  9. Azacitidine

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndrome

    phase 3 small molecule completed

    1 trial

  10. Azetukalner

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    3 trials

  11. Azetukalner

    Xenon Pharmaceuticals

    Bipolar Disorder

    phase 3 small molecule active

    1 trial

  12. Azetukalner

    Xenon Pharmaceuticals

    Bipolar Depression

    phase 3 small molecule active

    1 trial

  13. Azilsartan

    Takeda Pharmaceuticals International AG

    Pediatric Hypertension

    phase 3 small molecule completed

    2 trials

  14. Azilsartan Medoxomil

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    7 trials

  15. Azilsartan Medoxomil and amlodipine

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  16. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    2 trials

  17. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    4 trials

  18. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Safety

    phase 3 small molecule completed

    1 trial

  19. Azilsartan medoxomil and olmesartan

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  20. Azilsartan medoxomil with or without add-on chlorthalidone

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  21. Azilsartan medoxomil/placebo

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  22. BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  23. BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  24. BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources